Literature DB >> 2551551

Reactivity of anti-neutrophil cytoplasmic autoantibodies with HL-60 cells.

L A Charles1, R J Falk, J C Jennette.   

Abstract

Anti-neutrophil cytoplasmic autoantibodies (ANCA) react with antigens in the cytoplasm of neutrophils and monocytes, and are found in the blood of patients with necrotizing vasculitis and pauci-immune necrotizing and crescentic glomerulonephritis. The standard techniques for ANCA analysis use human polymorphonuclear leukocytes (PMN) as a source for antigen. A comparison was made between ANCA reactivity with human PMN and HL-60 cells. Fifty-five ANCA-positive and 17 ANCA-negative sera were reacted with HL-60 cells in an indirect immunofluorescence microscopy assay to assess the ability of HL-60 cells to distinguish between positive and negative reactivity and between the two major types of ANCA. The HL-60 cell method agreed with a PMN method in all but one instance. In an enzyme immunoassay, HL-60 primary granules could be used to detect ANCA. Evidence is also presented that the perinuclear staining of HL-60 cells and neutrophils by ANCA with anti-myeloperoxidase specificity is caused by the nucleophilic properties of myeloperoxidase. Reactivity with HL-60 cells further elucidates the antigen specificity of both types of ANCA and indicates that HL-60 cells are a suitable tissue culture cell line for investigating the pathobiology of ANCA.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2551551     DOI: 10.1016/0090-1229(89)90054-8

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  16 in total

Review 1.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

2.  A classification-based machine learning approach for the analysis of genome-wide expression data.

Authors:  James Lyons-Weiler; Satish Patel; Soumyaroop Bhattacharya
Journal:  Genome Res       Date:  2003-03       Impact factor: 9.043

Review 3.  The antigenic significance and methods of detection of the anti-neutrophil cytoplasmic autoantibodies (ANCA).

Authors:  X Bosch; R A Asherson
Journal:  Postgrad Med J       Date:  1992-09       Impact factor: 2.401

Review 4.  Antineutrophil cytoplasmic antibody--a useful serological marker for vasculitis.

Authors:  J A Goeken
Journal:  J Clin Immunol       Date:  1991-07       Impact factor: 8.317

Review 5.  Antineutrophil cytoplasmic autoantibodies: immunobiological aspects.

Authors:  W L Gross; E Csernok; W H Schmitt
Journal:  Klin Wochenschr       Date:  1991-09-03

6.  Prevalence and characterization of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) directed against HMG1 and HMG2 in ulcerative colitis (UC).

Authors:  J Sobajima; S Ozaki; H Uesugi; F Osakada; H Shirakawa; M Yoshida; K Nakao
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

7.  Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1.

Authors:  K Yanase; R M Smith; A Puccetti; L Jarett; M P Madaio
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

8.  A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies.

Authors:  J A Savige; B Paspaliaris; R Silvestrini; D Davies; T Nikoloutsopoulos; A Sturgess; J Neil; W Pollock; K Dunster; M Hendle
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

9.  Serological profile of rheumatoid arthritis in west Africa.

Authors:  A O Adebajo; P J Charles; B L Hazleman; R N Maini
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

10.  Endothelial cells and renal epithelial cells do not express the Wegener's autoantigen, proteinase 3.

Authors:  W J King; D Adu; M R Daha; C J Brooks; D J Radford; A A Pall; C O Savage
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.